ACSS3 represses prostate cancer progression through downregulating lipid droplet-associated protein PLIN3

Current endocrine therapy for prostate cancer (PCa) mainly inhibits androgen/androgen receptor (AR) signaling. However, due to increased intratumoural androgen synthesis and AR variation, PCa progresses to castration-resistant prostate cancer (CRPC), which ultimately becomes resistant to endocrine t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Lijie, Song, Zhengshuai, Hu, Junyi, Liu, Lilong, Hou, Yaxin, Zhang, Xiaoping, Yang, Xiong, Chen, Ke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738848/
https://www.ncbi.nlm.nih.gov/pubmed/33391508
http://dx.doi.org/10.7150/thno.49384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738848/
https://www.ncbi.nlm.nih.gov/pubmed/33391508
http://dx.doi.org/10.7150/thno.49384

Ejemplares similares